Results from a large systematic review of first-line combination antiretroviral therapy (ART) in people living with HIV (PLHIV) have confirmed that the type of nucleoside reverse transcriptase inhibitor (NRTI) backbone, type of third agent, and higher baseline CD4 lymphocyte counts, are independently predictive of greater efficacy at week 48.1
All healthcare professionals understand that people living with HIV (PLHIV) present with an individual perspective of what it’s like to be on life-long antiretroviral therapy (ART). But what is it like to be living with HIV on an ART regimen? And would a person’s quality of life, daily functioning and other dimensions of health, be different if they were on a different regimen?
As the clinical trial efficacy of contemporary antiretroviral regimens consistently exceed 90%, the impact of therapy on an individual’s overall health, including sense of wellbeing, has become an important consideration for clinicians when prescribing HIV treatment.1
New data from almost 78,000 people enrolled in first-line HIV studies between 1994 and 2017, suggests that almost 30% needed to stop or change their initial ART regimen within 3 years. The authors note that while efficacy has improved over time, even with INSTI-based therapy, there is still a need to stop or change initial ART regimens within the first 3 years of treatment.1
A new analysis of outcomes in almost 78,000 people living with HIV (PLHIV), shows that the efficacy of first-line antiretroviral therapy (ART) continues to improve. However, the findings also highlight that phase 3 studies overestimate ‘real world efficacy’ and longer phase 4 studies in both resource-rich and resource-limited settings are required.1
Patient-reported outcomes (PROs) are well documented, well studied instruments that clinicians can start to implement today, according to Professor David Wohl from the University of North Carolina, Chapel Hill. In this second of a three-part series, Professor David Wohl discusses the importance of incorporating PROs into daily practice and future clinical trials.
New systematic review identifies ART dosing characteristics associated with greatest efficacy at 48 weeks
Once-daily administration of antiretroviral therapy (ART) regimens is associated with improved efficacy when compared with regimens requiring multiple daily doses, according to a new analysis of outcomes at week 48 in almost 78,000 people living with HIV (PLHIV). Furthermore, over three-quarters of PLHIV who started once-daily ART between 2011 and 2015 were still on their first regimen and had an undetectable viral load three years later. 1
With consistent efficacy associated with contemporary antiretroviral therapy (ART),1 many clinicians have shifted their focus to assessing patient reported outcomes (PROs) – the impact of medication(s) on an individual’s overall health and sense of wellbeing - in order to differentiate between treatment regimens.
In the final instalment of this three-part series, Dr Martin discusses the use of patient reported outcomes (PROs) in HIV research and the importance of using adequately validated tools.
Amid the growing use of quality measures, patient-reported outcomes (PROs) should not be overlooked as a potential tool to improve clinical care, according to Dr Hal Martin, Director of Clinical Research at Gilead Sciences, San Francisco, California. In this second of a three-part series, Dr Martin discusses how PRO questionnaires can be used in practice to more accurately identify issues faced by people living with HIV (PLHIV).